Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 13 от 222

Recruiting

Improving Menstrual and VAginal Health for All

Effects of Menstrual Products on the Vaginal Microbiome

A three-period crossover trial will study the effects of short-term use of 3 menstrual products (menstrual pad, tampon, menstrual cup) on the bacterial composition of the vaginal microbiome in three countries (Peru, Cameroon, and Switzerland). Each crossover period consists of two menstrual cycles, thus resulting in a 6-month trial. Participants will be randomly assigned to one of 6 exposure sequences (different order of products per sequence); in each sequence, participants will adopt each menstrual product for 2 menstrual cycles. Participants will provide vaginal microbiome samples via self-sample swabs at 3 points during each menstrual cycle. Given the crossover design of the study, there is not a dedicated control group.

Начало: 15.04.2026 Край: 31.12.2026 Възраст: 18–35 г.

Cameroon, Peru, Switzerland Swiss Tropical & Public Health Institute NCT06646185

Recruiting

Remotely-supervised Neuromodulation in PPA

Primary Progressive Aphasia(PPA) Progressive Aphasia Progressive Aphasia in Alzheimer's Disease Logopenic Progressive Aphasia (LPA) +2

The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia (lvPPA), a language disorder most often caused by Alzheimer's disease. The main questions the study aims to answer are: * Is combining remotely supervised transcranial direct current stimulation (tDCS) with virtual speech-language therapy feasible and acceptable for people with lvPPA? * Does this combined treatment lead to improvements in communication compared to speech-language therapy with sham (placebo) stimulation? * Do individual brain characteristics help predict who benefits most from this treatment? Researchers will compare participants who receive active tDCS plus virtual speech-language therapy to participants who receive sham (placebo) tDCS plus virtual speech-language therapy to see if active brain stimulation enhances communication outcomes. Participants will: * Complete speech-language therapy sessions delivered by video visit. * Receive either active or sham tDCS that is remotely supervised and completed at home. * Complete language and cognitive testing before and after treatment. * Undergo brain imaging and other assessments to help understand treatment response.

Начало: 15.04.2026 Край: 01.08.2029 Възраст: от 40 г.

United States Maya Henry NCT07260253

Recruiting

Sensory Motor Arousal Regulation Treatment (SMART) Study

PTSD Post-traumatic Stress Disorder

This study will investigate whether a movement and body-based treatment can benefit adults with Post-traumatic Stress Disorder (PTSD). The treatment is called Sensory Motor Arousal Regulation Treatment, or "SMART", and study participation involves 8 sessions of SMART, as well as pre-treatment, post-treatment, and 3-month follow-up assessments.

Начало: 15.04.2026 Край: 15.04.2028 Възраст: 18–65 г.

Canada London Health Sciences Centre Research Institute OR Law NCT06035809

Recruiting

Community Health Adaptation & Resilience Mobilization (CHARM) HeatWise

Heat Illness

Extreme heat events pose serious health risks, especially for communities with limited access to cooling, transportation, or social support. This study pilots and tests HEATwise, a heat preparedness program delivered at trusted community centers in Lake County, California, serving older adults, Tribal members, and people experiencing housing or economic hardship. HEATwise is a 12-week program which includes a group workshop on heat risks and preparedness, one-on-one resource navigation, a community celebration event, and a cooling and emergency supply kit. The pilot phase (2026) will assess feasibility and acceptability at three sites with approximately 60 participants. The full trial (2027-2028) will randomly assign eight sites to receive HEATwise immediately or after a delay, measuring whether the program increases protective behaviors, reduces heat-related symptoms, and strengthens resilience over 12 months.

Начало: 15.04.2026 Край: 02.06.2028 Възраст: от 18 г.

United States Public Health Institute, California NCT07500545

Recruiting Phase 1/2

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

T-cell Lymphomas

This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.

Начало: 15.04.2026 Край: 01.12.2029 Възраст: от 18 г.

China Dizal Pharmaceuticals NCT07496229

Recruiting

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

Oral Cavity Cancer

The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy. Participants will: * Undergo a research biopsy * Take pembrolizumab per standard of care prior to surgery

Начало: 15.04.2026 Край: 01.12.2027 Възраст: от 18 г.

United States University of Wisconsin, Madison NCT07343596

Recruiting Phase 3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Resectable Colon Cancer MSI-H/dMMR Colorectal Cancer

This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR colon cancer.

Начало: 15.04.2026 Край: 15.03.2031 Възраст: 18–75 г.

China Akeso NCT07412613

Recruiting

Social Media Support Groups for Adolescent Vaping Cessation

Vaping Vaping Cessation Nicotine Dependence

The purpose of this study is to pilot test feasibility and acceptability of the Quit the Hit Toolkit, a social media-based nicotine vaping cessation program for adolescents and young adults, adapted for use in community settings.

Начало: 15.04.2026 Край: 01.08.2026 Възраст: от 13 г.

United States University of California, San Francisco NCT07540780

Recruiting Phase 3

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar) peripheral or abdominal/renal arteries

Trial status: Authorised Diagnostic performance indicators, namely sensitivity and specificity for detecting clinically significant steno-occlusive disease of different vascular territories.

Начало: 15.04.2026 Възраст: от 18 г.

Czech Republic, France, Germany +4 Guerbet, Bracco Imaging S.p.A. 2024-518835-13-00

Recruiting Phase 1

A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

Healthy

This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose. The study includes adults with normal liver function and adults who have mild, moderate, or severe liver problems. By comparing these groups, researchers want to understand whether liver function changes how the medicine behaves in the body. People who join the study will receive one injection of the study medicine. They will stay at the study clinic for a short time and return for follow-up visits so doctors can do blood tests, physical exams, and safety checks. This study is not expected to provide direct medical benefit to participants. The information collected will help researchers develop future treatments and understand how this medicine may be used safely in people with liver disease.

Начало: 15.04.2026 Край: 09.07.2027 Възраст: 18–74 г.

United States Pfizer NCT07519135

Recruiting

THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins

Allergic Inflammatory

Background: Allergic and inflammatory conditions have been increasing over the years. Many factors may play a role in this. Every day, people are exposed to pollution and chemicals in our foods, clothing, and all of the cleaning, hygiene, and other products we use. Studies have suggested there may be links between these environmental exposures and allergic and inflammatory illnesses. Researchers want to know more about how these exposures affect our health. Objective: To learn how everyday exposure to common substances affects people s health. Eligibility: Healthy people aged 18 to 80 years. Design: Participants will have 2 stays in the hospital. Each stay will last 7 days, and the stays will be spaced 4 to 6 weeks apart. During both stays, participants will remain confined to their room. They will eat only food from the menu, and they will use only provided products for personal care. (They may bring their own electronic devices, such as their phone and computer.) One stay will be in a pure room. Participants will breathe filtered air, eat unprocessed foods, and use personal care products with fewer chemicals. One stay will be in a room that allows exposure to common environmental chemicals. Some participants will be limited to only 1 type of exposure: chemicals thought to affect only skin, gut, or respiratory health. Some participants will be exposed to all 3 types. Participants will undergo testing. Blood, skin cell, urine, mouth swabs, and stool samples will be taken. They will have lung tests, smell tests, and tests that measure the health of their skin. These tests will be repeated in outpatient visits 2 weeks after each hospital stay....

Начало: 15.04.2026 Край: 30.01.2031 Възраст: 18–80 г.

United States National Institute of Allergy and Infectious Diseases ( NCT07271381

Recruiting Phase 4

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

Helicobacter Pylori Infection Dyspepsia Peptic Ulcer Disease Helicobacter Pylori +1

The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia. The main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen. Researchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication. Participants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days. Four weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication. Drug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up. Participants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.

Начало: 15.04.2026 Край: 14.08.2026 Възраст: от 18 г.

Bangladesh Bangabandhu Sheikh Mujib Medical University, Dhaka, Ban NCT07537634

Recruiting

Body Clocks - Coordination of Peripheral and Central Oscillators

Circadian Dysregulation

The investigators are conducting an observational trial examining young women over the course of 28 days in which we are monitoring movement, sleep, heart rate, oxygen saturation, gut physiology, light, and menstrual cycle. The inter- and independence of the cyclicity of these variables with each other, the circadian cycle, the menstrual cycle, and the sleep cycle will be tested.

Начало: 15.04.2026 Край: 30.09.2026 Възраст: 18–30 г.

United States Stanford University NCT07459764

Recruiting

A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer

Adult Cancer Patients Right Atrial Clot

The researchers are doing this study to see how well cardiac magnetic resonance imaging (CMR) scans can be used to examine the properties of central venous catheter-associated right atrial clot (RA clot). This could help doctors decide on the best treatment options.

Начало: 15.04.2026 Край: 01.04.2029 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT07549477

Recruiting Phase 2

Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Trial status: Authorised Plasma concentration-time profiles, and PK parameters of LB-208., Response according to the revised European LeukemiaNet (ELN) Response Criteria in AML (Döhner et al., 2022) and revised International Working Group 2023 (IWG 2023) in HR-MDS (Zeidan, Platzbecker, et al., 2023). Response for all patients will be assessed by the site Investigators. Safety, and toxicity will be described by observed frequency and severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0., including dose limiting toxicity (DLT) rate, adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation.

Начало: 15.04.2026 Възраст: от 18 г.

Spain Aop Orphan Pharmaceuticals GmbH 2025-523396-38-00

Recruiting Phase 3

A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome

Rett syndrome

Trial status: Authorised Change from Baseline to Week 14 in Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) score, Change from Baseline to Week 14 in Observer-Reported Communication Ability (ORCA) score, Caregiver Global Impression of Change – Seizure (CaGIC-Seizure) score at Week 14, Incidence of Treatment-emergent adverse event (TEAEs), Incidence of serious TEAEs, Incidence of TEAEs leading to discontinuation, Incidence of related TEAEs, Change from Baseline in QT interval corrected using Fridericia’s formula (QTcF) interval on 12-lead ECG at Week 14, Treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD), Treatment-emergent Doppler ECHO results meeting the FDA case definition of pulmonary arterial hypertension (PAH) >35mmHg Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score, Clinical Global Impression of Change (CGIC) Score at Week 14

Начало: 15.04.2026 Възраст: 18–64 г.

Belgium, France, Germany +2 UCB Biosciences Inc. 2025-523157-34-00

Recruiting Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified Recurrent Primary Mediastinal Large B-Cell Lymphoma Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma +4

This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Epcoritamab is a so-called bispecific antibody, a molecule that can bind simultaneously to two different receptors (proteins present on the cell surface). Epcoritamab binds to a receptor called CD3 with one part of the antibody and to a receptor called CD20 with another part of the antibody. CD3 is expressed on T cells, which are important cells of the immune system that help the body fight cancers and infections. CD20 is expressed on the surface of DLBCL cells. By simultaneous binding to CD3 and CD20, epcoritamab brings T cells and DLBCL cells close together and activates the T cells to kill the lymphoma cells. Rituximab is a so-called monoclonal antibody, a molecule that binds to a single receptor. Like epcoritamab, rituximab binds to CD20. After binding to CD20, rituximab activates the immune system to kill the lymphoma cell through several different mechanisms. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Giving epcoritamab-R-GemOx as therapy before an autologous stem cell transplant may help kill cancer cells in the body and help make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

Начало: 15.04.2026 Край: 15.10.2029 Възраст: от 18 г.

United States City of Hope Medical Center NCT07365306

Recruiting

Improving Information Sharing Between Family Caregivers and Home Care Aides

Shared Care

This study will assess the feasibility and acceptability of delivering a home care role and preference guide to up to 50 family caregivers and home care aides of persons living with disability for the purpose of identifying roles between family caregivers and home care aides.

Начало: 14.04.2026 Край: 31.08.2027 Възраст: от 18 г.

United States Johns Hopkins Bloomberg School of Public Health NCT07227558

Recruiting

In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

Cardiac Arrest

This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.

Начало: 14.04.2026 Край: 01.12.2030 Възраст: от 18 г.

Switzerland Insel Gruppe AG, University Hospital Bern NCT07434726

Recruiting

Thrive Person-Centered Planning Program for Young Adults With Fetal Alcohol Spectrum Disorders

Fetal Alcohol Spectrum Disorders

This study evaluates the Thrive person centered planning program for young adults with fetal alcohol spectrum disorders. Participants are randomized to either an immediate start or delayed start group for the psychoeducation phase. Following this phase, participants are randomized again to receive the intervention in either an individual or group based format. Participants complete repeated online assessments at multiple timepoints over approximately 10 months to evaluate whether the program improves goal setting, social support, and quality of life.

Начало: 14.04.2026 Край: 31.08.2028 Възраст: 18–25 г.

United States University of Rochester NCT07016009

1 … 11 12 13 14 15 … 222